Patents by Inventor Donglai Yang

Donglai Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FORMS OF RIFAXIMIN AND USES THEREOF
    Publication number: 20140141081
    Abstract: The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: June 27, 2013
    Publication date: May 22, 2014
    Inventors: Karen S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
  • FORMS OF RIFAXIMIN AND USES THEREOF
    Publication number: 20140011828
    Abstract: The present invention relates to Rifaximin amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: October 3, 2012
    Publication date: January 9, 2014
    Inventors: Karen S. Gushurst, Donglai Yang, Melanie Janelle Bevill, Nathan Carl Schultheiss, Giuseppe Claudio Viscomi
  • Forms of rifaximin and uses thereof
    Patent number: 8569326
    Abstract: The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: October 29, 2013
    Assignee: Salix Pharmaceuticals, Ltd.
    Inventors: Karen S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
  • Forms of rifaximin and uses thereof
    Patent number: 8486956
    Abstract: The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Grant
    Filed: February 19, 2010
    Date of Patent: July 16, 2013
    Assignee: Salix Pharmaceuticals, Ltd
    Inventors: Karen S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
  • FORMS OF RIFAXIMIN AND USES THEREOF
    Publication number: 20130066079
    Abstract: The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: August 23, 2012
    Publication date: March 14, 2013
    Applicant: Salix Pharmaceuticals, Ltd.
    Inventors: Karen S. Gushurst, Donglai Yang, Melanie Roe, Nathan Schultheiss, Petinka Vlahova, Jeffrey S. Stults, Travis L. Houston
  • FORMS OF RIFAXIMIN AND USES THEREOF
    Publication number: 20120316334
    Abstract: The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: August 16, 2012
    Publication date: December 13, 2012
    Applicant: SALIX PHARMACEUTICALS, LTD
    Inventors: Karen S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
  • FORMS OF RIFAXIMIN AND USES THEREOF
    Publication number: 20120076857
    Abstract: The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: September 6, 2011
    Publication date: March 29, 2012
    Applicant: SALIX PHARMACEUTICALS, LTD.
    Inventors: Karen S. Gushurst, Donglai Yang, Melanie Roe, Nathan Schultheiss, Petinka Vlahova, Jeffrey S. Stults, Travis L. Houston
  • Forms of rifaximin and uses thereof
    Patent number: 8067429
    Abstract: The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Grant
    Filed: February 25, 2009
    Date of Patent: November 29, 2011
    Assignee: Salix Pharmaceuticals, Ltd.
    Inventors: Karen S. Gushurst, Donglai Yang, Melanie Roe, Nathan Schultheiss, Petinka Vlahova, Jeffrey S. Stults, Travis L. Houston
  • Salts and Crystal Forms
    Publication number: 20110053997
    Abstract: The present invention relates to novel salts of the compound (R)-5-(2-Aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione, polymorphs of the salts and methods of their preparation.
    Type: Application
    Filed: December 5, 2008
    Publication date: March 3, 2011
    Inventors: Alexander Beliaev, David Alexander Learmonth, Melanie J. Roe, Petinka Vlahova, Eric Hagen, Valeriya Smolenskaya, Donglai Yang
  • FORMS OF RIFAXIMIN AND USES THEREOF
    Publication number: 20100239664
    Abstract: The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: February 25, 2009
    Publication date: September 23, 2010
    Applicant: SALIX PHARMACEUTICALS, LTD.
    Inventors: Karen S. Gushurst, Donglai Yang, Melanie Roe, Nathan Schultheiss, Petinka Vlahova, Jeffrey S. Stults, Travis L. Houston
  • FORMS OF RIFAXIMIN AND USES THEREOF
    Publication number: 20100174064
    Abstract: The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: February 19, 2010
    Publication date: July 8, 2010
    Applicant: SALIX PHARMACEUTICALS, LTD.
    Inventors: Karen S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
  • Crystalline forms of tiagabine hydrochloride
    Publication number: 20080064727
    Abstract: The present invention provides 16 new crystalline forms of tiagabine hydrochloride.
    Type: Application
    Filed: August 16, 2007
    Publication date: March 13, 2008
    Applicant: Cephalon, Inc.
    Inventors: Scott Childs, Leonard Chyall, Karen Gushurst, R. Haltiwanger, Robert McKean, Donglai Yang
  • Crystalline and amorphous forms of tiagabine
    Publication number: 20080051435
    Abstract: The present invention provides 24 new forms of tiagabine, including 22 new crystalline forms of tiagabine and its salts, an amorphous form of tiagabine free base, and a cocrystal form of tiagabine hydrochloride with 2-furancarboxylic acid. The present invention further provides a process for preparing each of the new tiagabine forms. The present invention further provides a pharmaceutical composition containing at least one of the new tiagabine forms, and a process for the preparation thereof. The present invention further provides a method of treating a disease related to GABA uptake in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of at least one of the new tiagabine forms.
    Type: Application
    Filed: August 16, 2007
    Publication date: February 28, 2008
    Applicant: Cephalon, Inc.
    Inventors: Scott Childs, Karen Gushurst, R. Haltiwanger, Robert McKean, Donglai Yang